{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:14:00Z","timestamp":1787591640953,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ctrv.2024.102715","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:35:25Z","timestamp":1709638525000},"page":"102715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["How to manage waldenstr\u00f6m\u2019s macroglobulinemia in 2024"],"prefix":"10.1016","volume":"125","author":[{"given":"Alexander","family":"Grunenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-9012","authenticated-orcid":false,"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102715_b0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0010","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720-48.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"10.1016\/j.ctrv.2024.102715_b0015","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/leu.2013.36","article-title":"How to manage Waldenstrom's macroglobulinemia","volume":"27","author":"Buske","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2024.102715_b0020","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022017235","article-title":"How we use Genomics and BTK-Inhibitors in the Treatment of Waldenstrom Macroglobulinemia","author":"Treon","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","article-title":"Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria","volume":"60","author":"Treon","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ctrv.2024.102715_b0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstrom's Macroglobulinema: chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2024.102715_b0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2023.03.005","article-title":"Report of consensus panel 1 from the 11(th) International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naive patients","volume":"60","author":"Buske","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ctrv.2024.102715_b0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenstr\u00f6m's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenstr\u00f6m's Macroglobulinemia","author":"Buske","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0045","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102715_b0050","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Lerchenm\u00fcller C, Hensel M, Goerner M, Buske C, Schulz H, et al. Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenstr\u00f6m's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). Blood. 2019;134 343.","DOI":"10.1182\/blood-2019-121909"},{"key":"10.1016\/j.ctrv.2024.102715_b0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/2040620716654102","article-title":"Ibrutinib in Waldenstrom macroglobulinemia: latest evidence and clinical experience","volume":"7","author":"Castillo","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.ctrv.2024.102715_b0060","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102715_b0065","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0075","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102715_b0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.seminhematol.2023.03.003","article-title":"Report of consensus panel 2 from the 11th international workshop on Waldenstrom's macroglobulinemia on the management of relapsed or refractory WM patients","volume":"60","author":"D'Sa","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ctrv.2024.102715_b0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstrom macroglobulinemia: Etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2024.102715_b0090","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/bjh.18643","article-title":"Dose reductions in patients with Waldenstrom macroglobulinaemia treated with ibrutinib","volume":"201","author":"Sarosiek","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2024.102715_b0095","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05\u2013180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0100","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0105","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.hoc.2018.05.013","article-title":"High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenstrom Macroglobulinemia","volume":"32","author":"Kyriakou","year":"2018","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.ctrv.2024.102715_b0115","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0120","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-09-806463","article-title":"First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival","volume":"131","author":"Pika","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0125","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/j.bbmt.2018.12.003","article-title":"Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis","volume":"25","author":"Sidiqi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2024.102715_b0130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14492","article-title":"Investigation and management of IgM and Waldenstr\u00f6m-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel","volume":"176","author":"D'Sa","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2024.102715_b0135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in Previously Treated Waldenstrom Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0140","doi-asserted-by":"crossref","unstructured":"Scarf\u00f2 L, Patel MR, Eyre TA, Jurczak W, Lewis D, Gastinne T, et al. P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED\/REFRACTORY WALDENSTR\u00d6M MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1\/2 BRUIN STUDY. Hemasphere. 2023;7.","DOI":"10.1097\/01.HS9.0000971328.85267.0f"},{"key":"10.1016\/j.ctrv.2024.102715_b0145","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-174375","article-title":"Ibrutinib and venetoclax as primary therapy in symptomatic treatment naive Waldenstrom macroglobulinemia","author":"Castillo","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0150","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0155","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(22)00385-0","article-title":"Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma","volume":"23","author":"Buske","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0160","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102715_b0165","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2024.102715_b0170","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hon.3153","article-title":"CAR T-cell therapy in large B cell lymphoma","volume":"41","author":"Boardman","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0175","first-page":"10","article-title":"CD19-directed chimeric antigen receptor T cell therapy in Waldenstr\u00f6m macroglobulinemia: a preclinical model and initial clinical experience","author":"Palomba","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2024.102715_b0180","doi-asserted-by":"crossref","first-page":"iv270","DOI":"10.1093\/annonc\/mdy322","article-title":"Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Kastritis","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0185","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0190","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0195","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Lerchenm\u00fcller C, Hensel M, Goerner M, Buske C, Schulz H, et al. Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenstr\u00f6m's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). Blood. 2019;134:343-.","DOI":"10.1182\/blood-2019-121909"},{"key":"10.1016\/j.ctrv.2024.102715_b0200","doi-asserted-by":"crossref","first-page":"1833 -","DOI":"10.1182\/blood.V126.23.1833.1833","article-title":"Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia","volume":"126","author":"Treon","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0205","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0210","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0215","first-page":"2772","article-title":"Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia","volume":"130","author":"Meid","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102715_b0220","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","article-title":"Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia","volume":"24","author":"Castillo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102715_b0225","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2024.102715_b0230","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0235","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2024.102715_b0240","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102715_b0245","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2024.102715_b0250","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/01.HS9.0000847388.33116.c7","article-title":"P1130: acalabrutinib in treatment-naive or relapsed\/refractory waldenstr\u00f6m macroglobulinemia: 5-year follow-up of a phase 2","volume":"6","author":"Owen","year":"2022","journal-title":"SINGLE-ARM STUDY HemaSphere"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:30:31Z","timestamp":1759656631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":50,"alternative-id":["S0305737224000422"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102715","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to manage waldenstr\u00f6m\u2019s macroglobulinemia in 2024","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102715"}}